Close

Acadia Pharmaceuticals (ACAD) PT Raised to $53 at Oppenheimer as Pivotal Studies Combine

May 27, 2020 7:16 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $53.00 (from $48.00) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login